What is Zymeworks's payments for repurchase of common stock?

Zymeworks (ZYME) reported payments for repurchase of common stock of $76.15M in Q1 2026.

What does payments for repurchase of common stock mean?

The total cash outflow used by the company to buy back its own shares from the open market or through private transactions. This activity is typically used to return capital to shareholders or to offset the dilutive impact of employee stock-based compensation.

Zymeworks ZYME Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

Charles River LaboratoriesCRL

$208.29M-41.0%

Other financials

Income statement

See full

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

See full

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

See full

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

See full

Market cap$1.79B+125%

Profitability

See full

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

See full

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zymeworks's payments for repurchase of common stock?: Zymeworks (ZYME) reported payments for repurchase of common stock of $76.15M in Q1 2026.
What does payments for repurchase of common stock mean?: The total cash outflow used by the company to buy back its own shares from the open market or through private transactions. This activity is typically used to return capital to shareholders or to offset the dilutive impact of employee stock-based compensation.